Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

FORGOTTEN HISTORY: Biomarin pharmaceutical inc - Caught on Camera

PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment

On Saturday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released new Phase 3 PEGASUS study results on Saturday.

Benzinga

BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030

On Tuesday, Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) reported second-quarter adjusted earnings of $1.44, up 50% year over year, beating the consensus of 85 cents and sales of $825.41 million, up 16%, beating the consensus of $760.39 million.

Benzinga

3 Pharmaceutical Stocks With Blockbuster Drug Potential

The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors might consider adding three well-positioned biotech stocks such as Vertex Pharmaceuticals (VRTX), BioMarin Pharmaceutical (BMRN), and Gilead Sciences (GILD), for potential gains. Learn more….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Niche Biotech Stocks Redefining Innovation

The biotech market offers great investment potential due to innovative advancements in genetic profiling, biologics, CRISPR technology, and rare disease treatments driving strong demand and growth. Therefore, investing in strong biotech stocks like Halozyme Therapeutics (HALO), BioMarin Pharmaceutical (BMRN), and United Therapeutics (UTHR) could be wise. Read on.

StockNews.com

3 Biotech Stocks With Huge Upside Based on Analyst Price Targets

The biotech sector’s long-term growth is fueled by strong government support, increasing funding and M&A activities, and rapid AI adoption. Therefore, quality biotech stocks Royalty Pharma (RPRX), BioMarin Pharmaceutical (BMRN), and Biogen (BIIB) with major upside could be ideal additions to your portfolio. Keep reading.

StockNews.com

3 Biotech Stocks Wall Street Predicts Will Skyrocket

Biotech companies could gain the financial flexibility to accelerate their innovations with the Fed’s recent rate cut. To capitalize on this opportunity, consider investing in fundamentally sound biotech stocks Biogen (BIIB), Royalty Pharma (RPRX), and BioMarin Pharmaceutical (BMRN), that are poised to skyrocket. Learn more.

StockNews.com

3 Healthcare Stocks With High Analyst Price Targets

Recent innovations, successful trials, and increased research and development spending in the healthcare sector further boost the sector’s appeal today. Given this momentum, investors might consider investing in stocks with high analyst price targets, such as Pfizer (PFE), Biogen (BIIB), and BioMarin Pharmaceutical (BMRN). Read on….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Undervalued Biotech Stocks Ready for a Breakout

The biotech industry's future appears bright due to advancements in biochemical and pharma technologies, AI integration, rising targeted treatments, and increased R&D spending driving breakthroughs. Therefore, it could be wise to invest in undervalued biotech stocks such as Harmony Biosciences Holdings (HRMY), United Therapeutics (UTHR), and BioMarin Pharmaceutical (BMRN). Read…

StockNews.com

3 Biotech Stocks With Sky-High Price Targets

The biotech sector is primed for growth, fueled by numerous advancements in genetic engineering and rising investment in research and development of personalized medicine. Hence, quality biotech stocks, BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), and Corcept Therapeutics (CORT) with sky-high price targets might be solid buys. Read more….

StockNews.com

3 Biotech Stocks Gaining Altitude and Interest

This year, the biotech industry anticipates a resurgence with increased M&A, FDA approvals, and AI-driven innovations. Given the industry’s rosy prospects, biotech stocks BioMarin Pharmaceutical (BMRN), ANI Pharmaceuticals (ANIP), and Genmab A/S (GMAB), gaining significant altitude and interest, could be ideal buys. Read on.

StockNews.com

3 B-Rated Biotech Stocks to Boost Your Bottom Line

The biotech industry’s growth prospects look promising due to innovative drugs and therapies, government initiatives, and technological advancements. Therefore, investors could consider buying fundamentally strong biotech stocks BioMarin Pharmaceutical (BMRN), Illumina (ILMN), and Harmony Biosciences (HRMY). These stocks are B-rated (Buy) in our proprietary rating system. Read on.

StockNews.com

Eyeing Growth? Check Out These 3 Biotech Stock Buys

Robust government support coupled with rapid tech advancements is bolstering the biotech sector. Hence, investors eyeing growth might buy fundamentally solid biotech stocks Theratechnologies (THTX), Equillium (EQ), and BioMarin Pharmaceutical (BMRN), with massive growth potential. Read on.

StockNews.com

3 Biotech Stocks Making Major Moves on Wall Street

The biotechnology industry is experiencing significant growth, fueled by government initiatives, rising investments and tech advancements. Therefore, it could be wise to consider fundamentally strong biotech stocks Shionogi & Co (SGIOY), Equillium (EQ), and BioMarin Pharmaceutical (BMRN), which are making major moves on wall street. Read more.

StockNews.com

Are These 4 Biotech Stocks Worth Buying in 2024?

The need for innovative healthcare solutions, personalized medicines and treatments, and the use of advanced technologies will propel the biotech industry forward. Amid this backdrop, let’s explore the investment potential of biotech stocks TG Therapeutics (TGTX), Galapagos (GLPG), BioMarin Pharmaceutical (BMRN), and United Therapeutics (UTHR).

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Biotech Stocks Showing Promising Returns for October

Technological advancements and the growing investment in developing healthcare infrastructures are expected to boost the biotech industry. Therefore, it could be wise to buy fundamentally strong biotech stocks Halozyme Therapeutics (HALO), BioMarin Pharmaceutical (BMRN), and United Therapeutics (UTHR). Read more.

StockNews.com

3 Biotech Stocks Offering Potential for Gains

Solid foothold of personalized medicine, increasing prevalence of chronic diseases, favorable government initiatives, and rapid digital transformation are opening new avenues for biotech companies. Thus, it could be wise to invest in fundamentally sound biotech stocks BioMarin Pharmaceutical (BMRN), Shionogi (SGIOY), and Exelixis (EXEL)for potential gains. Read on….

StockNews.com

3 Brilliant Biotech Stocks to Buy for Your Portfolio

The biotech industry is flourishing on the backs of positive clinical trials and new developments. Thus, it could be beneficial to add fundamentally robust biotech stocks BioMarin Pharmaceutical (BMRN), Equillium (EQ), and Organogenesis Holdings (ORGO) to your portfolios. Read more….

StockNews.com

3 Biotech Stocks With Great Value

The global demand for healthcare and biotech products continues to grow, owing to factors such as increasing chronic diseases and a greater focus on personalized medicine. Therefore, it might be wise to check out fundamentally sound biotech stocks BioMarin Pharmaceutical (BMRN), Exelixis, Inc. (EXEL), and Theratechnologies (THTX), currently trading at…

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Biotech Stocks Poised to Skyrocket

On the backs of successful trials and breakthrough therapies, the biotech market is poised to thrive. Therefore, scooping up the shares of fundamentally sound biotech stocks such as BioMarin Pharmaceutical (BMRN), Incyte Corp. (INCY), and Innoviva (INVA) could be beneficial. Read more….

Benzinga

BioMarin Achieves Record Q1 Sales Driven By Recently Approved Achondroplasia Therapy

BioMarin Pharmaceutical Inc's (NASDAQ:BMRN) Q1 sales reached $519 million, up 7% Y/Y, beating the consensus of $507.52 million. BioMarin said that the increase was achieved "despite continued erosion of the U.S. Kuvan market." Kuvan is indicated for phenylketonuria. Kuvan still brought in $59.3 million but down from $70.8 million a year ago.…

Benzinga

BioMarin Clocks Flat Q4 Sales Despite Erosion oF US Kuvan Market

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) reported a 1% Y/Y decrease in Q4 revenue to $449.8 million, beating the consensus estimate of $442.39 million. The decline was attributable to lower sales from Kuvan and Naglazyme, cushioned by higher revenues from Aldurazyme, Vimizim, and Palynziq. Kuvan sales decreased 23% to $ 68.5 million, primarily due…

Benzinga

FDA Asks For More Data To Resolve BioMarin's Gene Therapy Clinical Hold

BioMarin Pharmaceutical Inc (NASDAQ: BMRN) said that the

Benzinga

BioMarin Sells Priority Review Voucher For $110M

BioMarin Pharmaceutical Inc (NASDAQ: BMRN) has agreed to sell the Rare Pediatric Disease Priority Review Voucher (PRV)

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Vertex Pharmaceuticals Incorporated

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.